Tag

Off Label

All articles tagged with #off label

Media Frenzy Triggers 2,000% Surge in Leucovorin Use for Autism
health15 days ago

Media Frenzy Triggers 2,000% Surge in Leucovorin Use for Autism

A UCSD study using the Epic Cosmos database found leucovorin prescriptions for children with autism rose more than 2,000% after a February 2025 TV segment and subsequent September 2025 White House promotion, despite no proven autism benefit; the FDA later approved leucovorin only for cerebral folate transport deficiency in March 2026. The study highlights how media coverage and political messaging can rapidly shift off-label prescribing before large, definitive trials exist, and it does not assess patient outcomes.

GLP-1s for a Few Pounds: A Cautious Dive into the New Weight-Loss Trend
health1 month ago

GLP-1s for a Few Pounds: A Cautious Dive into the New Weight-Loss Trend

A Glamour-style piece documents how GLP-1 drugs once reserved for medical weight management are being used off-label for cosmetic goals, including compounded versions and microdosing via telehealth. It weaves patient anecdotes with medical perspectives, highlights risks like side effects and gut–microbiome effects, and shows a growing push-pull between health benefits and the influencer-driven hype. The author begins a low-dose Zepbound plan under a doctor’s supervision and reports initial weight loss, while stressing the need for cautious, evidence-based use as these drugs become more accessible.

Genomics-guided off-label cancer therapy shows benefit in defined subgroups (DRUP trial)
health1 month ago

Genomics-guided off-label cancer therapy shows benefit in defined subgroups (DRUP trial)

In the Drug Rediscovery Protocol (DRUP), 1,610 patients with advanced solid tumors were treated with 37 off-label drugs matched to actionable genomic alterations. Of 1,363 evaluable patients, the clinical benefit rate was 34.9% and the objective response rate was 15.7%, with median progression-free and overall survival of 3.4 months and 8.2 months, respectively; grade 3+ treatment-related adverse events occurred in 28.4%, leading to discontinuation in 9.4%. Exceptional responders (7.0%) appeared across molecular subgroups, and some results supported Dutch reimbursement. The authors emphasize meaningful benefit in defined molecular contexts despite overall modest activity, advocating structured, data-generating frameworks, earlier intervention, biomarker refinement, and international collaboration to guide safe use and potential label expansion.

Leucovorin: The Autism Treatment Approved Amidst Controversy
health8 months ago

Leucovorin: The Autism Treatment Approved Amidst Controversy

Families have been using leucovorin, a drug originally for cancer, to treat autism symptoms, gaining attention after President Trump mentioned it. While some studies suggest potential benefits, the evidence is limited and the FDA's recent move to update the drug's label is considered unusual and controversial due to weak supporting data. Experts emphasize the need for more research and caution in its use.